Somatic mutation status at KRAS, BRAF and NRAS affects prognosis in patients with advanced colorectal cancer (aCRC) and it has been presumed that different variants in the same gene confer similar prognostic outcomes. Here, we studied inter-and intra-locus variant co-occurrence and variant-specific differences in survival and clinicopathology by analysing 2,157 patients with aCRC. We found significant differences between variants in BRAF (c.1781A>G [p.D594G] versus c.1799T>A [p.V600E]) and NRAS (mutant codons 12 and 13 versus codon 61) both in terms of co-occurrence with KRAS mutations and in their influence on survival.
INTRODUCTION
The only routinely used prognostic marker for survival after diagnosis of colorectal cancer (CRC) is clinical stage, which combines depth of tumour invasion, nodal status and distant metastasis (1) . In stage 4 disease, Köhne's index based on performance status, white blood cell count, alkaline phosphatase levels and number of metastatic sites has been proposed (2) . Other factors thought to influence survival include lifestyle (3, 4) , systemic inflammatory response to the tumour (5) , tumour immunologic environment (6) , and the germline (7) and somatic (8-11) molecular profiles. By studying patients with advanced CRC (aCRC) from the Medical Research Council (MRC) COIN trial, we previously showed that the somatic mutation status at KRAS and BRAF, and microsatellite instability (MSI), conferred poor prognosis irrespective of treatment: overall survival (OS, trial enrolment to death) KRAS mutant 14.4 months (12) , BRAF mutant 8.8 months (12), MSI 9.3 months (13), all wild type 20.1 months (12) . We also showed that neither individual somatic mutations, nor mutations grouped by codon or gene, affected response to cetuximab (13) .
It remains unclear whether there are intra-locus, variant-specific differences in survival and this has been difficult to study for the less frequently mutated loci (such as c.1781A>G [p.D594G] in BRAF) due to the large numbers of samples required to make statistically robust associations. Here, we studied the influence of individual or codon specific somatic mutations in KRAS, BRAF and NRAS in 2,157 patients with aCRC from COIN (12) and COIN-B (14) .
MATERIALS AND METHODS

Patients and samples
We prepared tumour DNA samples from unrelated patients with aCRC from the MRC clinical trials COIN (NCT00182715) (12) and COIN-B (NCT00640081) (14) , as previously described (12, 13) . All patients had either previous or current histologically confirmed primary adenocarcinomas of the colon or rectum, together with clinical or radiological evidence of advanced and/or metastatic disease, or had histologically/cytologically confirmed metastatic adenocarcinomas, together with clinical and/or radiological evidence of a colorectal primary tumour. COIN patients were randomised 1:1:1 to receive continuous oxaliplatin and fluoropyrimidine chemotherapy, continuous chemotherapy plus cetuximab, or intermittent chemotherapy. COIN-B patients were randomised 1:1 to receive intermittent chemotherapy plus continuous cetuximab or intermittent chemotherapy plus intermittent cetuximab. All patients gave informed consent for their samples to be used for bowel cancer research (approved by REC [04/MRE06/60]).
Somatic analyses
We previously screened for somatic mutations in KRAS (codons 12, 13 and 61), BRAF (codons 594 and 600) and NRAS (codons 12, 13 and 61) using a combination of Pyrosequencing and Sequenom (13); for samples analysed by both technologies (n=1,612), genotype concordance in KRAS was 99% (8,642/8,719 calls were concordant). MSI status was determined using the markers BAT-25 and BAT-26 (13) .
Mutation co-occurrence, survival and statistical analyses
We sought inter-and intra-locus correlations between somatic KRAS, BRAF and NRAS mutations and MSI status. Data was analysed using R (http://www.rproject.org). Corrplot was used to create a correlation matrix plot (recode from car was used to recode the data into binary format) and Survfit, survdiff and coxph.test from the OIsurv package and ggsurv from the GGally package were used to create and analyse the survival curves. To avoid potential confounding affects from other mutant loci, KRAS mutants (versus wild type) were analysed on a BRAF and NRAS wild type background; BRAF mutants (versus wild type) were analysed on a KRAS 
RESULTS
We screened for somatic KRAS, BRAF and NRAS mutations and for MSI status in aCRCs from 2,157 patients from the clinical trials COIN and COIN-B. In total, we 
Inter-and intra-genic mutation correlations
All mutations in KRAS, regardless of whether analysed individually or by codon, showed similar effects in terms of mutual exclusivity ( Supplementary Figure) . Codon 12 (4 of 627 mutant CRCs), 13 (4 of 161) and 61 (2 of 35) mutations were rarely found together.
Only specific mutations in BRAF (c.1799T>A [p.V600E]) and NRAS (codon 61 mutations) shared this characteristic. Only 1% (2/178) of BRAF c.1799T>A (p.V600E) CRCs had RAS mutations compared to 47% (894/1908) of BRAF wild type CRCs (p<2.2e -16 , p<1.1e -13 after correction for multiple testing). In contrast, more BRAF c.1781A>G (p.D594G) mutations co-occurred with RAS mutations (14% [3/21] ) as compared to c.1799T>A (p.V600E) (p=9.0e -03 ); albeit less commonly than found in BRAF wild-type CRCs (p=3.0e -03 ). We noted one case of KRAS c.37G>A (p.G13S) which co-occurred with BRAF c.1799T>A (p.V600E) (p=2.5e -03 as compared to other KRAS mutations [1/812 co-occurred]). For NRAS, only 5% (3/60) of codon 61 mutant CRCs had KRAS mutations compared to 43% (10/23) of codons 12 and 13 mutant CRCs (p=7.9e -05 , p=0.04 after correction); the latter being at similar level to that found in wild type CRCs (40% [808/2018], p=0.98).
We also observed differences in the relationship between BRAF mutations and MSI status. respectively; four of these remained significant after correction for multiple testing (Table 1) . When grouped by codons, both codon 12 and 13 mutations conferred poor prognosis (HR 1.44, 95% CI 1.28-1.61, p=6.4e -10 , p=1.9e -08 after correction, and HR 1.53, 95% CI 1.26-1.86, p=1.5e -05 , p=4.5e -04 after correction, respectively), whereas codon 61 mutations did not (HR 1.23, 95% CI 0.84-1.81, p=0.28) ( Table 1) ; these intra-locus differences were not significant. c.1799T>A (p.V600E) in BRAF was strongly associated with poor prognosis (HR 2.60, 95% CI 2.06-3.28, p=1.0e -15 , p=3.0e -14 after correction, median reduction in survival 320 days) ( Fig.1 ), whereas c.1781A>G (p.D594G) was not (HR 1.30, 95% CI 0.73-2.31, p=0.37); this intra-locus difference was significant (p=0.04) ( Table 1) .
Although individual NRAS mutations showed no differences in survival, when grouped by codon, codon 61 mutations conferred poor prognosis (HR 1.47, 95% CI 1.09-1.99, p=0.01, median reduction in survival 131 days) ( Fig.1 ), whereas codons 12 and 13 mutations did not (HR 1.29, 95% CI 0.64-2.58, p=0.48); however, this intra-locus difference was not significant (p=0.73).
Patients with MSI CRCs had worse prognosis compared to those with stable tumours (HR 1.86, 95% CI 1.22-2.83, p=4.0e -03 ), in agreement with our previous study (13) .
For all analyses described herein, there were no significant differences measured using heterogeneity tests when the analyses were performed using date of diagnosis to death instead of OS ( Supplementary Table S1 ) or when split by cetuximab use ( Supplementary Table S2 ). ) as compared to wild type CRCs; the correlations for right colon and rectum remained significant after correction for multiple testing (Table 3 ).
Clinicopathological analyses
KRAS
In terms of intra-locus differences, there was a significant difference between (Table 3 ). There was no significant difference between the sites of metastases associated with these mutations.
NRAS
There was no difference between the frequency of NRAS mutant and wild type CRCs in the site of the primary tumour (Table 4 ). However, more NRAS mutant CRCs were associated with metastases in the lung (11% [43/400]) as compared to liver only (4% [10/272], p=1.4e -03 ).
In terms of individual codons, codon 12 and 13 mutant CRCs showed similar clinicopathology to wild type CRCs ( (Table 4 ).
There were no significant differences in clinicopathology between codons 12 and 13 versus codon 61 mutant CRCs.
MSI
More MSI CRCs were found in the right colon (41% [12/29] (Table 5 ).
DISCUSSION
Variants in BRAF and NRAS have been presumed to confer similar oncogenic and prognostic outcomes; however, here we demonstrate clear intra-locus differences.
For BRAF, c.1799T>A (p.V600E) was almost mutually exclusive of RAS mutations and was associated with poor prognosis. In contrast, c.1781A>G (p.D594G) was more often associated with RAS mutations and had no apparent influence on survival. However, c.1781A>G (p.D594G) is unlikely to be benign and more likely to be hypomorphic, as it had significantly fewer co-occurrences with RAS mutations as compared to BRAF wild type CRCs. Interestingly, our data are consistent with a recent report showing that patients with codon 594 or 596 mutated tumours had longer OS compared to those with c.1799T>A (p.V600E) CRCs (15) . There are clear biological differences between these mutant codons to support our observed pathological differences; p.V600E increased extracellular signal-regulated kinase (ERK) and nuclear factor kappaB (NFκB) signalling and the transformation of NIH3T3 cells, whereas p.D594V failed to activate ERK (16) and did not affect NFκB signalling nor NIH3T3 transforming activity (17) .
Others have reported that NRAS mutant patients have shorter OS as compared to wild type patients (HR 1.91, 95% CI 1.39-3.86; p=1.0e -03 ) (18) . Here, we noted a more complex relationship; NRAS codon 61 mutations, which were rarely associated with KRAS mutations, conferred a poor prognosis, but codons 12 and 13 mutations, which co-occurred with KRAS mutations at similar frequencies to wild type CRCs, had little influence on survival. Together, our data suggest that NRAS codons 12 and 13 mutations may have a minor role in colorectal tumourigenesis. Interestingly, using mouse models others have shown that endogenous levels of Nras p.Q61R, but not Nras p.G12D, were able to efficiently drive in vivo melanomagenesis (19) , supporting their differing biological effects.
We have also shown that different mutant loci are associated with differences in the clinicopathology of the primary tumours and/or their sites of metastases. For example, in agreement with two recent reports (20, 21) , we observed more KRAS mutant CRCs in the caecum (70%) and, to a lesser extent, in the right colon (58%), as compared to the left colon (38%). It has been suggested that different somatic profiles are associated with different clinicopathology, by influencing the tumour's biological behaviour (22) . Here, we focussed on intra-locus differences and found a significant difference between c.1781A>G (p.D594G) and c.1799T>A (p.V600E) in BRAF in the location of the primary tumour providing additional support for these variants having different biological effects. particularly in the outcomes of mutations in BRAF and NRAS. These data need to be considered in patient management. Mutations were analysed on an NRAS and BRAF wild type background. 1 There was a significant difference between KRAS mutant CRCs in the location of the primary tumour (p=6.4e -14 ) and in the sites of metastases (p=4.6e -04 ) as compared to wild type CRCs. Percentages are shown in regular parentheses ( 2 some patients had multiple metastases so percentages do not add up to 100%). p-values that remained significant after correction for multiple testing are shown in square parentheses. NA -not applicable. Discrepancies in column totals are due to patients with multiple mutations or due to missing data. Mutations analysed on a RAS wild type and MSS background. 1 There was a significant difference between BRAF mutant CRCs in the location of the primary tumour (p=1.2e -13 ) and in the sites of metastases (p=0.03) as compared to wild type CRCs. Percentages are shown in regular parentheses ( 2 some patients had multiple metastases so percentages do not add up to 100%). p-values that remained significant after correction for multiple testing are shown in square parentheses. NA -not applicable. Discrepancies in column totals are due to patients with multiple mutations or due to missing data. Mutations analysed on a KRAS and BRAF wild type background. 1 There was a significant difference between NRAS mutant CRCs in the sites of metastases (p=2.5e -03
) as compared to wild type CRCs. Percentages are shown in regular parentheses ( 2 some patients had multiple metastases so percentages do not add up to 100%). p-values that remained significant after correction for multiple testing are shown in square parentheses. NA -not applicable. Discrepancies in column totals are due to patients with multiple mutations or due to missing data. MSI status was analysed on an RAS and BRAF wild type background. 1 There was a significant difference between MSI CRCs in the location of the primary tumour (p=2.5e -04 ) and in the sites of metastases (p=0.02) as compared to MSS CRCs. Percentages are shown in regular parentheses ( 2 some patients had multiple metastases so percentages do not add up to 100%). p-values that remained significant after correction for multiple testing are shown in square parentheses. NA -not applicable. Discrepancies in column totals are due to patients with multiple mutations or due to missing data. 
